Salix Pharmaceuticals, which is embroiled in a fight to resist a hostile takeover bid by Axcan Pharmaceuticals of Canada, promoted its CFO and announced increasing sales for its lead drugs on Wednesday.

Adam Derbyshire, the chief financial officer, is now senior vice president of finance and administration. Derbyshire has been with the company for three years.

Salix also said sales of Colazal, its treatment for ulcerative colitis, set a record for sales the week of May 23 with more than 5,000 prescription orders. Colazal also has been endorsed by a health care maintenance network servicing some 8 million individuals and more than 450,000 physicians.

Salix (Nasdaq: SLXP) stock closed down 23 cents, to $11.64.